Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition

19 August 2026 · By · Wire by Fusion42

Published

19 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 20 August 2026 · Fusion42 review

Tempus AI's stock surged following the successful Phase 3 cancer trial results by Merck and Moderna, which validated the critical sequencing technology of Personalis that Tempus recently acquired for $1.5 billion.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You need to act now if your startup works with genomic sequencing or personalised medicine infrastructure as Tempus’s Personalis acquisition unlocks direct commercial leverage from Moderna’s mRNA cancer therapy breakthrough.

◆ Coverage

1 source · 19 Aug 2026

◆ Related on Wire

◆ Topics

Biotechcancer-therapymrnaacquisitiongenomicsclinical-trial